Back to Journals » Drug Design, Development and Therapy » Volume 15

Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways

Total article views   HTML views PDF downloads Totals
3,786 Dovepress* 3,324+ 671 3,995
PubMed Central* 462 137 599
Totals 3,786 808 4,594
*Since 7 January 2021

View citations on PubMed Central and Google Scholar